Leerink Partners Initiates Coverage On Ironwood Pharmaceuticals with Market Perform Rating, Announces Price Target of $5
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has initiated coverage on Ironwood Pharmaceuticals with a Market Perform rating and set a price target of $5.
September 09, 2024 | 12:55 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Leerink Partners has initiated coverage on Ironwood Pharmaceuticals with a Market Perform rating and a price target of $5, indicating a neutral outlook.
The Market Perform rating suggests that the stock is expected to perform in line with the market. The price target of $5 provides a specific valuation expectation, which is crucial for investors. This neutral rating and specific price target are significant for investors in IRWD.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100